Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/DAD.0000000000001865 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pan-cancer analysis shows that BCAP31 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types.
Front Immunol
December 2024
Department of Otolaryngology, the Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu, China.
Background: B-cell receptor-associated protein 31 (BCAP31) is a widely expressed transmembrane protein primarily located in the endoplasmic reticulum (ER), including the ER-mitochondria associated membranes. Emerging evidence suggests that BCAP31 may play a role in cancer development and progression, although its specific effects across different cancer types remain incompletely understood.
Methods: The raw data on BCAP31 expression in tumor and adjacent non-tumor (paracancerous) samples were obtained from the Broad Institute Cancer Cell Line Encyclopedia (CCLE) and UCSC databases.
Integrating traditional biomarkers and emerging predictors to assess neoadjuvant chemotherapy efficacy in breast cancer: a multifactorial analysis of Ki-67, CDK4, EGFR, TILs and ctDNA.
BMC Womens Health
December 2024
Department of Blood Transfusion, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Objective: This study aimed to analyse the correlation between the expression of cell proliferation-associated antigen (Ki-67), cell cycle protein-dependent kinase 4 (CDK4), epidermal growth factor receptor (EGFR), tumour-infiltrating lymphocytes (TILs) and circulating tumour DNA (ctDNA) with the outcome and prognosis of patients with breast cancer (BC) undergoing neoadjuvant chemotherapy (NACT).
Methods: We retrospectively analysed the clinicopathological data of 231 patients with BC who underwent preoperative NACT at XX Hospital between 1 January 2018 and 31 December 2021. Logistic regression models were used to analyse factors influencing NACT efficacy.
The deep learning radiomics nomogram helps to evaluate the lymph node status in cervical adenocarcinoma/adenosquamous carcinoma.
Front Oncol
December 2024
Department of Radiology, Jinshan Hospital, Fudan University, Shanghai, China.
Objectives: The accurate assessment of lymph node metastasis (LNM) can facilitate clinical decision-making on radiotherapy or radical hysterectomy (RH) in cervical adenocarcinoma (AC)/adenosquamous carcinoma (ASC). This study aims to develop a deep learning radiomics nomogram (DLRN) to preoperatively evaluate LNM in cervical AC/ASC.
Materials And Methods: A total of 652 patients from a multicenter were enrolled and randomly allocated into primary, internal, and external validation cohorts.
S100A8 promotes tumor progression by inducing phenotypic polarization of microglia through the TLR4/IL-10 signaling pathway in glioma.
J Natl Cancer Cent
December 2024
Department of Neurosurgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Background: S100A8 is a member of the S100 protein family and plays a pivotal role in regulating inflammation and tumor progression. This study aimed to comprehensively assess the expression patterns and functional roles of S100A8 in glioma progression.
Methods: Glioma tissues were collected from 98 patients who underwent surgical treatment at Fudan University Shanghai Cancer Center.
Possibility of Human Epidermal Growth Factor Receptor 2 Expression as a Treatment Selection Indicator in Early Triple-Negative Breast Cancer.
Cureus
November 2024
Department of Breast Surgery, Osaka Rosai Hospital, Osaka, JPN.
Background This study aimed to evaluate the relationship among human epidermal growth factor receptor 2 (HER2) expression level, pathological complete response (pCR) rate of neoadjuvant chemotherapy, and prognosis in early-stage triple-negative breast cancer (TNBC). Methodology This retrospective study analyzed the relationship among HER2 expression level, pCR rate, clinicopathological factors, and prognosis in 39 patients who were diagnosed with TNBC between 2012 and 2020 at Osaka Rosai Hospital and underwent surgery after neoadjuvant chemotherapy (NAC). Results Patients' age ranged 33-86 (median = 57) years, and the observation period ranged 5-130 (median = 60) months.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!